[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-345920-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-345920-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","therapy-related-mutational-signatures-in-subsequent-neoplasms-among-survivors-of-childhood-cancer","Therapy-Related Mutational Signatures in Subsequent Neoplasms among Survivors of Childhood Cancer","","Childhood cancer survivors face a substantially elevated risk of therapy-related subsequent neoplasms (SN). Whole-genome, exome, and RNA sequencing were used to analyze 200 breast, meningioma, and thyroid SNs arising a median of 26.4 years after treatment among 160 survivors. Meningioma and thyroid SNs showed enriched driver rearrangements, including NF2-disrupting events and radiation-suggestive kinase fusions. Radiation associated with higher ID5 insertion–deletion signatures, nitrogen mustard exposure with increased “flat” SBS5 signatures in breast and meningioma SNs, and platinum therapy in meningioma with NF2 splice-site variants. Multi-sample analysis revealed intrapatient meningioma heterogeneity with clonally independent tumors.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/therapy-related-mutational-signatures-in-subsequent-neoplasms-among-survivors-of-childhood-cancer/345920/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/therapy-related-mutational-signatures-in-subsequent-neoplasms-among-survivors-of-childhood-cancer/345920.png","ImageObject",300,407,{"name":42,"@type":43},"Seraphina","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What kinds of subsequent neoplasms were analyzed in the study?","Question",{"text":63,"@type":64},"The study analyzed 200 subsequent neoplasms involving breast, meningioma, and thyroid among childhood cancer survivors.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How long after childhood cancer treatment did the subsequent neoplasms typically develop?",{"text":68,"@type":64},"They developed a median of 26.4 years after childhood cancer treatment.",{"name":70,"@type":61,"acceptedAnswer":71},"Which treatment exposures were linked to specific mutational signature changes?",{"text":72,"@type":64},"Radiation correlated with increased insertion–deletion signature ID5, nitrogen mustard treatment correlated with elevated flat SBS5 signatures in breast and meningioma SNs, and platinum therapy correlated with NF2 splice-site variants in meningioma.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},345920,1790192621,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962075114101,"https://ap-avatar.wpscdn.com/avatar/e000253a75eb197efd?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780044092746381165","ReseaRch aRticle  \nTherapy-Related Mutational Signatures in Subsequent Neoplasms among Survivors of  \nChildhood Cancer   \nSamuel W. Brady1,2, Michael A. Arnold3,4, Mingjuan Wang5, Ramzi Alsallaq2, Li Dong2, Mohammad Aslam Khan1, Wentao Yang2, Kayla L. Stratton6, Wei Liu5, Yan Chen7, Emily Plyler2, Jacob A. Steele2, Brent B. Powers2, David Rosenfeld2, Michael N. Edmonson2, Yuan Feng2, Nadezhda V. Terekhanova2, Kohei Hagiwara2, Sasi Arunachalam2, Heather L. Mulder2, Deo Kumar Srivastava5, Michael Rusch2, Vikki G. Nolan7, Aaron McDonald7, Yadav Sapkota7, Maria M. Gramatges8,9, Lucie M. Turcotte10, Cindy Im10, Rebecca M. Howell11, John Easton2, Xiaotu Ma2, Zhaoming Wang2,7, Wendy M. Leisenring6, Miriam Conces12, Joseph P. Neglia10, Yutaka Yasui7, Smita Bhatia13, David W. Ellison14, Jinghui Zhang2, and Gregory T. Armstrong7  \nChildhood cancer survivors have a heightened risk of developing subsequent  \nneoplasms (SN) related to therapy. We analyzed whole-genome, exome, and RNA sequencing of 200 breast, meningioma, and thyroid SNs, which developed a median of 26.4 years after childhood cancer, among 160 survivors. Meningioma and thyroid SNs were enriched for driver gene rearrangements compared with de novo tumors, including NF2-disrupting alterations and kinase fusions potentially induced by radiation. Radiation correlated with increased insertion–deletion signature ID5 . Nitrogen mustard treatment correlated with elevated “flat”signature SBS5 in breast and meningioma SNs; in vitro , these agents caused an unresolved flat signature associated with multiple flat signatures from the Catalogue of Somatic Mutations in Cancer. In meningioma, platinum therapy correlated with NF2 splice-site variants. Analysis of 19 multisample survivors revealed intrapatient heterogeneity in meningioma, including clonally independent tumors. These results demonstrate the long-term impact of childhood cancer treatment on the genomes of SNs developing in adulthood, which may guide SN treatment and prevention.  \nSigNifiCANCe: This represents the most comprehensive genomic characterization of SNs from childhood cancer survivors to date, revealing the mutagenic impact of multiple therapies on the SN genome, including the potential impact of nitrogen mustards such as cyclophosphamide. These results may guide the optimization of future cancer treatment regimensto prevent SN development.  \nSee related commentary by Bertrums and van Boxtel, p. 1483  \nintRoduction  \nAlthough >85% of children diagnosed with cancer will become >5-year survivors (1, 2), it is well established that these survivors have over a fivefold increased risk of developing a malignant subsequent neoplasm (SN) compared with  \n1Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children’s Research Hospital, Memphis, Tennessee. 2Department of Computational Biology, St. Jude Children’s Research Hospital, Memphis, Tennessee.  \n3Department of Pathology, University of Colorado, Anschutz Medical Campus, Aurora, Colorado. 4Department of Pathology and Laboratory Medicine, Children’s Hospital Colorado, Aurora, Colorado. 5Department of Biostatistics, St. Jude Children’s Research Hospital, Memphis, Tennessee.  \n6Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington. 7Department of Epidemiology and Cancer Control, St. Jude Children’s Research Hospital, Memphis, Tennessee. 8Department of Pediatrics, Baylor College of Medicine, Houston, Texas. 9Cancer and Hematology Center, Texas Children’s Hospital, Houston, Texas. 10Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota. 11Department of Radiation Physics, University of Texas MD Anderson Cancer Center, Houston, Texas. 12Department of Pathology and Laboratory Medicine, Nationwide Children’s Hospital, Columbus, Ohio. 13Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama.  \n14Department of Pathology, St. Jude Children’s Research Hospital, Memphis, Tennessee.  \nJ. Zhang, G.T. Armst","cbCaimf7x740gL95","https://ap.wps.com/l/cbCaimf7x740gL95","pdf",9980666,21,"English","# Introduction\n## Therapy-related risk of subsequent neoplasms\n## Genomic features and mutational signatures\n## Study approach and sequencing analyses\n## Key findings across SN subtypes","[{\"question\":\"What kinds of subsequent neoplasms were analyzed in the study?\",\"answer\":\"The study analyzed 200 subsequent neoplasms involving breast, meningioma, and thyroid among childhood cancer survivors.\"},{\"question\":\"How long after childhood cancer treatment did the subsequent neoplasms typically develop?\",\"answer\":\"They developed a median of 26.4 years after childhood cancer treatment.\"},{\"question\":\"Which treatment exposures were linked to specific mutational signature changes?\",\"answer\":\"Radiation correlated with increased insertion–deletion signature ID5, nitrogen mustard treatment correlated with elevated flat SBS5 signatures in breast and meningioma SNs, and platinum therapy correlated with NF2 splice-site variants in meningioma.\"}]","Therapy-Related Mutational Signatures in Subsequent Neoplasms among Survivors of Childhood Cancer | PDF",1790059397,53,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4e61d971b4de2b089bcbc3651a9b982b.webp",983,1315,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e3bcd19b6c1aaf03d9e1686a5133f5b5.webp",982,1314,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0279de075d7257ee3d9864b4faf72d43.webp",981,1312,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7cd7c97aca18115cfc037dbe16cc2c24.webp",980,1311]